{"id":18720,"date":"2020-12-18T00:27:24","date_gmt":"2020-12-18T00:27:24","guid":{"rendered":"http:\/\/evaggelatos.com\/?p=18720"},"modified":"2020-12-18T00:27:39","modified_gmt":"2020-12-18T00:27:39","slug":"h-ivermectin-%ce%ad%ce%bd%ce%b1-%ce%b1%ce%bd%cf%84%ce%b9%cf%80%ce%b1%cf%81%ce%b1%cf%83%ce%b9%cf%84%ce%b9%ce%ba%cf%8c-%ce%b5%ce%bc%cf%80%ce%bf%ce%b4%ce%af%ce%b6%ce%b5%ce%b9-%cf%84%ce%b7%ce%bd-%ce%b5","status":"publish","type":"post","link":"https:\/\/evaggelatos.com\/?p=18720","title":{"rendered":"H Ivermectin \u03ad\u03bd\u03b1 \u03b1\u03bd\u03c4\u03b9\u03c0\u03b1\u03c1\u03b1\u03c3\u03b9\u03c4\u03b9\u03ba\u03cc, \u03b5\u03bc\u03c0\u03bf\u03b4\u03af\u03b6\u03b5\u03b9 \u03c4\u03b7\u03bd \u03b5\u03be\u03ac\u03c0\u03bb\u03c9\u03c3\u03b7 \u03c4\u03bf\u03c5 COVID 19"},"content":{"rendered":"

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro<\/em><\/span><\/h1>\n
\n
\n
\n
Author links open overlay panel<\/span>Leon<\/span>Caly<\/span>a<\/sup><\/span><\/span><\/a>Julian D.<\/span>Druce<\/span>a<\/sup><\/span><\/span><\/a>Mike G.<\/span>Catton<\/span>a<\/sup><\/span><\/span><\/a>David A.<\/span>Jans<\/span>b<\/sup><\/span><\/span><\/a>Kylie M.<\/span>Wagstaff<\/span>b<\/sup><\/span><\/span><\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n

<\/a><\/p>\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
https:\/\/doi.org\/10.1016\/j.antiviral.2020.104787<\/a>Get rights and content<\/a><\/div>\n
\n
Under a Creative Commons license<\/a><\/div>\n
open access<\/div>\n<\/div>\n
<\/section>\n
<\/section>\n
<\/div>\n
\n
\n

Highlights<\/h2>\n
\n
\n
\u2022<\/dt>\n
\n

Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.<\/em><\/p>\n<\/dd>\n

\u2022<\/dt>\n
\n

A single treatment able to effect ~5000-fold reduction in virus at 48\u00a0h in cell culture.<\/p>\n<\/dd>\n

\u2022<\/dt>\n
\n

Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.<\/p>\n<\/dd>\n

\u2022<\/dt>\n
\n

Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.<\/p>\n<\/dd>\n<\/dl>\n<\/div>\n<\/div>\n

\n

Abstract<\/h2>\n
\n

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring\/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro<\/em>, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2\u00a0h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48\u00a0h. Ivermectin therefore warrants further investigation for possible benefits in humans.<\/p>\n<\/div>\n<\/div>\n<\/div>\n